Literature DB >> 20848076

[Targeted therapy of urological tumours. Experimental field or established therapeutic approach?].

M W Kramer1, S Krege, I Peters, A S Merseburger, M A Kuczyk.   

Abstract

Unlike conventional systemic chemotherapies, the aim of targeted therapeutic approaches is not to address general mechanisms involved in cellular replication. In contrast, they aim at such regulatory pathways that have been identified to be involved in the progression of human malignant disease. Whereas the application of targeted therapeutic modalities is well established for the treatment of metastatic renal cell cancer, only very few data on their clinical efficacy during the treatment of other urological tumours such as prostate and bladder cancer are currently available. The aim of this paper is to reflect on the current status regarding the relevance of targeted therapeutic approaches during the treatment of urological cancers of different origin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20848076     DOI: 10.1007/s00120-010-2397-2

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  35 in total

1.  Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab.

Authors:  C Kollmannsberger; H Pressler; F Mayer; L Kanz; C Bokemeyer
Journal:  Ann Oncol       Date:  1999-11       Impact factor: 32.976

2.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

Authors:  Maha Hussain; Catherine M Tangen; Primo N Lara; Ulka N Vaishampayan; Daniel P Petrylak; A Dimitrios Colevas; Wael A Sakr; E David Crawford
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

5.  A phase II clinical trial of sorafenib in androgen-independent prostate cancer.

Authors:  William L Dahut; Charity Scripture; Edwin Posadas; Lokesh Jain; James L Gulley; Philip M Arlen; John J Wright; Yunkai Yu; Liang Cao; Seth M Steinberg; Jeanny B Aragon-Ching; Jürgen Venitz; Elizabeth Jones; Clara C Chen; William D Figg
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

6.  Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT.

Authors:  Lawrence H Einhorn; Mary J Brames; Michael C Heinrich; Christopher L Corless; Ali Madani
Journal:  Am J Clin Oncol       Date:  2006-02       Impact factor: 2.339

7.  Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.

Authors:  Jeanny B Aragon-Ching; Lokesh Jain; James L Gulley; Philip M Arlen; John J Wright; Seth M Steinberg; David Draper; Jürgen Venitz; Elizabeth Jones; Clara C Chen; William D Figg; William L Dahut
Journal:  BJU Int       Date:  2009-01-09       Impact factor: 5.588

8.  KIT mutations are common in testicular seminomas.

Authors:  Kathleen Kemmer; Christopher L Corless; Jonathan A Fletcher; Laura McGreevey; Andrea Haley; Diana Griffith; Oscar W Cummings; Cecily Wait; Ajia Town; Michael C Heinrich
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

9.  Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis.

Authors:  P L Nguyen; P E Swanson; W Jaszcz; D M Aeppli; G Zhang; T P Singleton; S Ward; D Dykoski; J Harvey; G A Niehans
Journal:  Am J Clin Pathol       Date:  1994-02       Impact factor: 2.493

10.  RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis.

Authors:  Inga Peters; Kristina Rehmet; Nadine Wilke; Markus A Kuczyk; Jörg Hennenlotter; Tyark Eilers; Stefan Machtens; Udo Jonas; Jürgen Serth
Journal:  Mol Cancer       Date:  2007-07-16       Impact factor: 27.401

View more
  4 in total

1.  [Should cytoreductive nephrectomy be performed in patients with metastatic renal cell carcinoma and what is the scientific rationale?]

Authors:  N Gilbert; A S Merseburger; M W Kramer
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

Review 2.  [Hypertension and palmar plantar erythroderma. Management of adverse events of angiogenetic inhibitors in the treatment of renal cell carcinoma].

Authors:  N Rolfes; G Lümmen
Journal:  Urologe A       Date:  2011-11       Impact factor: 0.639

Review 3.  Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?

Authors:  George J Netto
Journal:  Nat Rev Urol       Date:  2011-12-13       Impact factor: 14.432

Review 4.  Emerging critical role of molecular testing in diagnostic genitourinary pathology.

Authors:  George J Netto; Liang Cheng
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.